Entries |
Document | Title | Date |
20080227861 | Inhibition of Allergic Contact Dermatitis By N-L-ALPHA-ASPARTYL-L-PHENYLALANINE 1-METHYL ESTER - It has now been found that N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester (APM) and/or one of its lower alkyl derivatives can be used to treat allergic contact dermatitis associated with irritating oils such as catechol-containing plant-derived antigens such as poison ivy, poison oak, poison sumac and Asian lacquer tree and oils containing capsaicin. Topical application of APM and/or derivative can reduce or alleviate the symptoms associated with irritation of the skin and/or mucous membranes caused by contact or inhalation of these oils or fumes from burning vegetation containing these oils. | 09-18-2008 |
20080249175 | N-Phenyloxamide derivatives - A compound represented by the following general formula (I) or a salt thereof, or a hydrate thereof or a solvate thereof having an inhibitory action against plasminogen activator inhibitor-1 (PAI-1): | 10-09-2008 |
20080280982 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses - The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like. | 11-13-2008 |
20080280983 | METHODS OF TREATING RETT SYNDROME - The present embodiments relate to methods for the treatment of Rett Syndrome. More specifically, the present embodiments relate to pivagabine for use in the treatment of Rett Syndrome. Some embodiments relate to treatment of a patient with Rett Syndrome. Other embodiments relate to treatment of the indications of Rett Syndrome. | 11-13-2008 |
20080287542 | Novel Isovaleramide Forms, Compositions Thereof, and Related Methods of Use - The invention provides novel isovaleramide forms. These forms include isovaleramide co-crystals, and solvates, hydrates, co-crystals, and polymorphs thereof. The invention also provides novel compositions comprising these novel forms and one or more suitable carriers. The invention also provides related methods of treatment or prevention. Compositions and methods of the invention have a number of uses, including the treatment or prevention of epilepsy and anxiety. | 11-20-2008 |
20080300308 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses - The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like. | 12-04-2008 |
20080319073 | COLONIC DELIVERY THERAPEUTIC AGENTS FOR INFLAMMATORY BOWEL DISEASE - The present invention discloses a therapeutic agent for inflammatory bowel disease, which is in the from of delivering 1 to 5 g of glutamine to the large intestine per one administration; and the therapeutic agent for inflammatory bowel disease with which an anti-inflammatory agent(s) is combined. This therapeutic agent for inflammatory bowel disease can safely and effectively treat inflammatory bowel disease including ulcerative colitis without increasing the frequency of bowel movements. | 12-25-2008 |
20080319074 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses - The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like. | 12-25-2008 |
20080319075 | Polymorphic forms of nateglinide - Provides are crystalline forms of nateglinide, labeled Forms A, C, D, F, G, I, J, K, L, M, N, O, P, Q, T, U, V, Y, α, β, γ, δ, ε, σ, θ and Ω, processes for their preparation and processes for preparation of other crystalline forms of nateglinide. Also provided are their pharmaceutical formulations and methods of administration. | 12-25-2008 |
20090018197 | METHODS FOR TREATING STATUS EPILEPTICUS AND RELATED CONDITIONS - The present invention is directed to the novel use of a class of peptide compounds for treating status epilepticus or related conditions, e.g. acute repetitive seizures, seizure clusters, etc. | 01-15-2009 |
20090018198 | METHOD FOR TREATING A MOTONEURON DISORDER - The present invention is directed to the use of a class of peptide compounds for treating amyotrophic lateral sclerosis (ALS) and other forms of motoneuron diseases and peripheral neuropathies. | 01-15-2009 |
20090030080 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states - This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of administering to a mammal in need of such treatment a compound selected from a series of disubstituted trans,trans 1,3-butadienes, 1,3-disubstituted perhydrobutadienes, 1,2-disubstituted trans ethylenes and 1,2 disubstituted ethanes and disubstituted propanes, each of which embodies, in common, the unique structural feature essential for the biological activity of these compounds. This invention also provides for pharmaceutical formulations that employ these novel compounds. | 01-29-2009 |
20090042987 | TREATMENT OF NEUROPATHIC PAIN - A method of decreasing neuropathic pain in a mammal, comprising administering to said mammal an effective amount of tranilast for a period of time sufficient to decrease pain. | 02-12-2009 |
20090042988 | PHARMACEUTICAL COMPOSITIONS CONTAINING A MEGLITINIDE COMPOUND FOR PREVENTING HEPATIC FIBROSIS - The present invention discloses pharmaceutical compositions for preventing, improving or treating hepatic fibrosis, hepatocellular degeneration or cirrhosis, which contain a meglitinide compound such as nateglinide. | 02-12-2009 |
20090082450 | DEUTERIUM-ENRICHED DICLOFENAC - The present application describes deuterium-enriched diclofenac, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-26-2009 |
20090088475 | Indanone derivatives that inhibit prolyl hydroxylase - Compounds of Formula I are useful inhibitors of HIF prolyl hydroxylases. Compounds of Formula I have the following structure: | 04-02-2009 |
20090105343 | Cancer Therapy And Medicaments Therefor - The present invention relates to a novel cancer therapy, particularly, but not exclusively, to a prostate, bladder and breast cancer therapy and to Compositions and medicaments for use in said therapy. In one aspect there is provided a method of treating a patient afflicted with cancer comprising administering to the patient a therapeutically effective amount of a nuclear receptor ligand and an HDAC (histone deacetylases) inhibitor wherein said nuclear receptor ligand is not a ligand for the vitamin D receptor. | 04-23-2009 |
20090143469 | SALTS OF NATEGLINIDE - The present invention relates to salts of organic acid, in particular salt of nateglinide, combined preparations comprising one or more salts of nateglinide and, optionally, one or more additional ingredients and the use thereof in pharmaceutical compositions for preventing or treating diabetes, cardiovascular disease, or conditions associated therewith. | 06-04-2009 |
20090156680 | Deodorants Containing Aminoacid Derivatives - A deodorant composition comprising an aminoacid compound of formula I or II and a carrier material. I R | 06-18-2009 |
20090197957 | Methods and compositions for the treatment of pain - The present invention relates generally to the area of pain management and more particularly, to a method of analgesia and agents useful for same. More particularly, the present invention relates to a method of analgesia utilising a compound of formula (I). The method of the present invention is useful, inter alia, in the therapeutic or prophylactic treatment of pain, including acute pain, chronic non-malignant pain and chronic malignant pain. Also provided are compounds for use in the method of the invention. | 08-06-2009 |
20090197958 | Sustained Release Particulate Oral Dosage Forms of (R) Baclofen and Methods of Treatment - Sustained release particulate oral dosage forms of (R)-baclofen prodrugs and methods of treating a disease comprising orally administering such dosage forms are disclosed. | 08-06-2009 |
20090197959 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS - Described herein are compounds that are antagonists of PGD | 08-06-2009 |
20090209648 | Phenylacetic Acid Derivatives - Compounds of formula (I) pharmaceutically acceptable salts thereof, and pharmaceutically acceptable esters thereof; which are useful for the treatment of COX-2 dependent disorders. | 08-20-2009 |
20090215899 | N-Phenyloxamide derivatives - A compound represented by the following general formula (I) or a salt thereof, or a hydrate thereof or a solvate thereof having an inhibitory action against plasminogen activator inhibitor-1 (PAI-1): | 08-27-2009 |
20090215900 | COMPOSITION AND METHOD FOR PROVIDING GLUTAMINE - A process for preparing a glutamine-supplemented food product by contacting water and a nutritive base that pre-dominantly comprises meat and carbohydrate with a peptide source of glutamine to form a wet mixture and heating the wet mixture at a temperature of from about 50° C. to about 105° C. for a time sufficient to cook the nutritive base. The process forms a cooked food composition comprising from about 60% to about 85% by weight water. The product is useful for feeding to an animal to increase glutamine absorption or to strengthen immune function. | 08-27-2009 |
20090234010 | MANUFACTURE PROCESS OF ORGANIC COMPOUNDS - The present invention relates to a method of preparing N-substituted salicylamides or derivatives thereof and their derivatives, e.g. their salts. In particular, the present invention relates to a method of preparing (N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC) and its corresponding disodium monohydrate. | 09-17-2009 |
20090234011 | N-ACETYLCYSTEINE AMIDE (NAC AMIDE) FOR THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH OXIDATIVE STRESS - Methods and compositions comprising N-acetylcysteine amide (NAC amide) and derivatives thereof are used in treatments and therapies for human and non-human mammalian diseases, disorders, conditions and pathologies. Pharmaceutically or physiologically acceptable compositions of NAC amide or derivatives thereof are administered alone, or in combination with other suitable agents, to reduce, prevent, or counteract oxidative stress and free radical oxidant formation and overproduction in cells and tissues, as well as to provide a new source of glutathione. | 09-17-2009 |
20090239950 | METHODS FOR SYNTHESIS OF PRODRUGS FROM 1-ACYL-ALKYL DERIVATIVES AND COMPOSITIONS THEREOF - The present invention provides a method for synthesizing 1-(acyloxy)-alkyl derivatives from 1-acyl-alkyl derivatives, which typically proceeds stereospecifically, in high yield, does not require the use of activated intermediates and/or toxic compounds and is readily amendable to scale-up. The current invention also provides 1-acyl-alkyl derivatives of known drug components and methods for synthesizing these 1-acyl-alkyl derivatives. | 09-24-2009 |
20090247637 | Novel Anthranilic Acid Derivatives - The invention is concerned with novel anthranilic acid derivatives of formula (I) | 10-01-2009 |
20090253794 | Fibroblast Activator, Collagen Production Promoter, Collagen Contraction Promoter, Hyaluronic Acid Production Promoter, ATP Production Promoter, Melanin Formation Inhibitor, and Agent for External Application to the Skin - The present invention is a fibroblast activator, collagen production promoter, collagen contraction promoter, hyaluronic acid production promoter, ATP production promoter or melanin formation suppressor, which contains, as an active ingredient, at least one kind of compound selected from the group consisting of conagenin, a conagenin derivative, and a pharmaceutically acceptable salt thereof, as well as a composition (skin external preparation, cosmetic, pharmaceutical product or food, which is a composition for the improvement of wrinkles or a whitening composition) containing such activator, promoter or melanin formation suppressor. | 10-08-2009 |
20090253795 | Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibiton of pain and inflammation - A method and solution for perioperatively inhibiting a variety of pain and inflammation processes during arthroscopic procedures. The solution preferably includes a vasoconstrictor that demonstrates substantial agonist activity at alpha adrenergic receptors and that is selected for peripheral (local) vasoconstriction and one or more additional pain and inflammation inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for peripheral vasoconstriction and inhibition of pain and/or inflammation while avoiding undesirable side effects associated with systemic application of larger doses of the agents. | 10-08-2009 |
20090253796 | METHOD FOR TREATING VASCULAR DISEASE - A medicament for prophylactic and/or therapeutic treatment of a vascular disease such as vascular restenosis and/or reocclusion after percutaneous transluminal coronary angioplasty using an intravascular stent, which comprises as an active ingredient a substance selected from the group consisting of retinoids and agents for controlling actions of retinoids such as 4-[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid or a salt thereof, or 4-[[[3,5-bis-(trimethylsilyl)phenyl]carbonyl]amino]benzoic acid or a salt thereof, wherein said substance has substantially no antiproliferative action on vascular endothelial cells, but substantially has antiproliferative action on vascular smooth muscle cells. | 10-08-2009 |
20090258946 | ELECTROSTATICALLY CHARGED NASAL APPLICATION MULTIPURPOSE PRODUCTS AND METHOD - A family of products designed to ameliorate sinusitis and allergic rhinitis, produced by combining certain chemical substances with existing products, thereby producing a synergistic effect and relief. The chemical substances create an electrostatically charged field around the nose and prevent allergens or pollutants from entering the nostrils to cause a reaction, illness, or discomfort for the user. Therefore, the Present Invention comprises products, which are applied to the face, and therefore around the nose and nasal passages, as well as those applied directly into the nose. These products include but are not limited to nasal sprays, rinses, washes, sunscreens, nasal strips, swabs (medicated and non-medicated), tissues, towelettes, cosmetics, and fragrances. Common nasal sprays often comprise saline solutions. Cosmetics comprise camouflage paint or theatrical makeup. The principle function of the Present Invention is to prevent harmful airborne particulates from entering the nose when either sprayed into the nose or applied to the face, nose, or nasal passages. | 10-15-2009 |
20090270505 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES - This invention relates to novel 4-dimethylaminobutyric acid derivatives of the formula | 10-29-2009 |
20090281186 | Composition and Method for Reducing Stress - The present invention relates to a composition and method for reducing stress, in a mammal, wherein said composition acts by modulating levels and activities of various neurotransmitters and enhancing the phosphotidyl-inositol second messenger system affected by neurotransmitters. The composition of the present invention comprises at least L-theanine, including derivatives of L-theanine, and inositol, including derivatives of inositol. | 11-12-2009 |
20090286881 | SELECTED BETAINES AND THEIR USES - A physiologically acceptable, sterile and pyrogen-free solution of betaine dissolved in a physiologically acceptable solvent, having a pH adjusted to from 5.0 to 8.0 with a betaine concentration of from 5 to 500 mg/ml. | 11-19-2009 |
20090306208 | PROPHYLACTIC OR THERAPEUTIC COMPOSITION FOR HEMOGLOBINURIA OR MYOGLOBINURIA - A prophylactic or therapeutic composition for hemoglobinuria or myoglobinuria which may occur in humans or animals upon loading of exercise or stress or the like is provided. | 12-10-2009 |
20090306209 | ENTERIC-COATED FORMULATIONS OF POLYETHYLENE GLYCOL AND ONE OR MORE SOLUBLE AMINO ACIDS FOR ORAL INGESTION AND ENHANCED UPTAKE OF SAME - Oral amino acid formulations comprising polyethylene glycol are enteric coated. Most preferred amino acids are leucine, glutamine, and arginine. The most preferred polyethylene glycols have an average molecular weight of from 3150 to 3685, although for particular formulation formulations and particular uses, the average molecular weight polyethylene glycols may range from 190 to 9000. | 12-10-2009 |
20090312422 | METHOD OF MODULATING CELLULAR ACTIVITY AND AGENTS USEFUL FOR SAME - Described is a rational design of therapeutic and/or prophylactic methods of treating conditions characterized by aberrant or otherwise unwanted microglial cell functioning and rational design methods for treating a range of neurological disorders which are characterized by nitric oxide induced neuronal damage. | 12-17-2009 |
20100004335 | ORAL PREPARATION FOR PREVENTING OR IMPROVING SKIN DRYNESS - An oral preparation for the prophylaxis or improvement of dry skin accompanied by atopic dermatitis, xeroderma, chapped hand, chapped skin and the like is provided. The present invention can provide an oral preparation for the prophylaxis or improvement of dry skin, which comprises citrulline or a salt thereof as an active ingredient. | 01-07-2010 |
20100016435 | HYBRID MOLECULES HAVING MIXED VITAMIN D RECEPTOR AGONISM AND HISTONE DEACETYLASE INHIBITORY PROPERTIES - Novel chemical agents are described. More specifically, hybrid molecules comprising a vitamin D receptor agonist moiety and an HDAC inhibitor moiety are described herein. | 01-21-2010 |
20100022650 | Benzamide Derivatives As EP4 Receptor Agonists - A compound of formula (I) or a pharmaceutically acceptable derivative thereof, | 01-28-2010 |
20100029767 | ANTHRANILIC ACID DERIVATIVES - Compounds of formula (I) are provided, wherein X is CH═CH, CH | 02-04-2010 |
20100041756 | METHOD OF MODULATING B CELL FUNCTIONING - The present invention relates generally to a method of modulating cellular functioning. More particularly, the present invention relates to a method of modulating B cell functioning, for example B cell proliferation, utilising an IDO-mediated tryptophan metabolite as herein defined (particular examples of such IDO-mediated tryptophan metabolites include 3-hydroxykynurenic acid, 3-hydroxyanthranilic acid, picolinic acid, quinolinic acid and tranilast). The method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by aberrant, unwanted or otherwise inappropriate B cell functioning such as antibody production, autoimmune conditions and B cell proliferation and neoplasias. In a related aspect, the present invention is directed to a method of therapeutically and/or prophylactically treating rheumatoid arthritis via the administration of the above-mentioned compounds. | 02-18-2010 |
20100048708 | TAMIBAROTENE CAPSULE PREPARATION - The present invention provides a practical preparation form of Tamibarotene and dosage form thereof, which exhibit high absorptivity by the body with minimized toxicity, and which are safe and stable without any risk of contamination. It is provided a Tamibarotene capsule preparation which encapsulates a composition comprising an oil component as its base and Tamibarotene as an active ingredient dissolved in the base. It is preferred that the oil component be propylene glycol fatty acid esters or polyethylene glycols. It is also preferred that the Tamibarotene capsule preparation comprise 0.1-50 mg/mL of the Tamibarotene based on the oil component. | 02-25-2010 |
20100063150 | Aflatoxin Production Inhibitor and Method for Controlling Aflatoxin Contamination Using the Same - An object of the present invention is to provide an aflatoxin production inhibitor that inhibits aflatoxin production specifically and efficiently, is highly safe, and is practical, and an efficient production method thereof; and a method for controlling aflatoxin contamination that uses the aflatoxin production inhibitor. | 03-11-2010 |
20100063151 | ACYLAMIDE COMPOUNDS HAVING SECRETAGOGUE OR INDUCER ACTIVITY OF ADIPONECTIN - The present invention provides acylamide compounds, prodrugs thereof, or pharmaceutically acceptable salts thereof; and an adiponectin inducer or secretagogue, and therapeutic methods by administering the same. | 03-11-2010 |
20100087535 | EXTERNAL COMPOSITION FOR SKIN - A moisturizing agent comprising one or more than one compound selected from the group consisting of lysyl-β-alanine represented by the following general formula (1) and a salt thereof: | 04-08-2010 |
20100093863 | USE OF CITRULLINE FOR PREVENTING AN INCREASE IN PROTEIN CARBONYLATION AND FOR TREATING DISEASES RESULTING THEREFROM - A method of using L-citrulline of the formula (I) for preparing a cosmetic composition, a food or nutraceutic composition or a pharmaceutical composition for treating diseases related to an increase in protein carbonylation, in particular for treating neurodegenerative diseases such as Alzheimer's or Parkinson's disease. | 04-15-2010 |
20100113597 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OF PROGRESS OF INTESTINAL CONSTRICTION ASSOCIATED WITH CROHN'S DISEASE - The present invention provides an oral pharmaceutical composition for inhibiting the progression of intestinal stricture associated with Crohn's disease. That is, the present invention relates to a pharmaceutical composition for inhibiting the progression of intestinal stricture associated with Crohn's disease which comprises as an active ingredient N-(3,4-dimethoxycinnamoyl)anthranilic acid (generic name: tranilast) or a pharmaceutically acceptable salt thereof. The present invention can provide a pharmaceutical composition useful as an agent for inhibiting the progression of intestinal stricture associated with Crohn's disease for medical therapy. | 05-06-2010 |
20100137442 | Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment - Sustained release particulate oral dosage forms of (R)-baclofen prodrugs and methods of treating a disease comprising orally administering such dosage forms are disclosed. | 06-03-2010 |
20100144881 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND - The invention provides crystalline solid forms of (S)-4-((2S,3S)-7-carbamoyl-1,1-diethyl-3-methoxy-1,2,3,4-tetrahydronaphthalen-2-ylamino)-2-cyclohexylmethyl-butyric acid. The invention also provides pharmaceutical compositions comprising such crystalline solid forms, methods of using such crystalline solid forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline solid forms. | 06-10-2010 |
20100168238 | PHARMACEUTICAL COMPOSITION CONTAINING PHLOROGLUCINOL AND PARACETAMOL - The invention relates to a pharmaceutical composition for oral or rectal administration, that contains phloroglucinol and paracetamol in a pharmaceutically acceptable carrier. The inventors have evidenced a synergy developed by these two active ingredients in antispasmodic therapy. | 07-01-2010 |
20100216886 | POLYMORPHS OF N2-(1,1'-BIPHENYL-4-YLCARBONYL)-N1-[2-(4-FLUOROPHENYL)-1,1-DIMETHYLETHYL]- -L-ALPHA-GLUTAMINE - Disclosed are novel polymorphic forms of N | 08-26-2010 |
20100286274 | Methods of Diagnosing, Monitoring and Treating Pulmonary Diseases - The invention includes methods of discriminating asthma from obstructive pulmonary disease, of treating pulmonary diseases, of treating cough, of assessing the efficacy of a treatment for an obstructive pulmonary disease, and of inhibiting activation of a P2-purinoreceptor (P2R). | 11-11-2010 |
20100298436 | EP2 Agonist from Non-Prostanoid Structures Designed as PGE2 Antagonists - An EP2-receptor agonist of the following structure is disclosed: | 11-25-2010 |
20100305207 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF - This invention relates to a novel compound which is a glycogen phosphorylase inhibitor and its use in the treatment of diabetes and other conditions associated therewith. The invention further relates to a pharmaceutical composition containing the compound and to processes for preparing the compound and pharmaceutical composition. | 12-02-2010 |
20100317736 | COMPOSITION OF THE SKIN EXTERNAL APPLICATION OR THE FOOD FOR ACCELERATING PROLINE RECYCLING BY CONTAINING THEANINE - Disclosed herein is a composition for promoting proline recycling, and more particularly, to a composition for external application to skin or cosmetic food comprising theanine as an active ingredient for promoting expression or activity of prolidase, which is an enzyme to promote proline recycling, thereby increasing collagen synthesis and restoring wrinkle. | 12-16-2010 |
20100324140 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES - The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like. | 12-23-2010 |
20110028552 | MEXILETINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF - The present invention concerns prodrugs of mexiletine (and mexiletine's active metabolite) with amino acids or peptides and pharmaceutical compositions containing such prodrugs. Methods for providing pain relief, treating arrhythmia, decreasing the adverse GI side effects associated with mexiletine, increasing the bioavailability of mexiletine, and improving the pharmacokinetic reproducibility of mexiletine with the aforementioned prodrugs are also provided. Oligopeptides incorporating lysine or arginine residues attached directly or indirectly through a glycine residue are also described herein. | 02-03-2011 |
20110034557 | ANTIMICROBIAL COMPOSITIONS AND USES THEREOF - Antimicrobial compositions and methods of using the compositions are described herein. The compositions include an antibacterial acyl amino acid. In some embodiments, the acyl amino acid is a fatty acylated glutamate. The methods herein include methods of using acyl amino acids for treating and preventing bacterial infections. | 02-10-2011 |
20110039933 | S1P-1 RECEPTOR AGONISTS - The invention provides compounds formula (I), their preparation, and their use as pharmaceutically active immuno-suppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or SIP receptors. | 02-17-2011 |
20110065795 | (1S,2S,3S,4R)-3-[(1S)-1-ACETYLAMINO-2-ETHYL-BUTYL]-4-UANIDINO-2-HYDROXYL-C- YCLOPENTYL-1-CARBOXYLIC ACID HYDRATES PHARMACEUTICAL USES THEREOF - The present invention relates to (1S,2S,3S,4R)-3-[(1S)-1-acetylamino-2-ethyl-butyl]-4-guanidino-2-hydroxy-cyclopentyl-1-carboxylic acid hydrates compounds, preparing methods thereof, pharmaceutical compositions containing said compounds and preparing methods thereof, and the clinical uses of said compounds as neuramidinase inhibitors for anti-influenza. | 03-17-2011 |
20110065796 | PRODRUGS OF GUANFACINE - Prodrugs of guanfacine with amino acids or short peptides, pharmaceutical compositions containing such prodrugs and a method for providing therapeutic benefit in the treatment of ADHD/ODD (attention deficient hyperactivity disorder and oppositional defiance disorder) with guanfacine prodrugs are provided herein. Additionally, methods for minimizing or avoiding the adverse gastrointestinal side effects associated with guanfacine administration, as well as improving the pharmacokinetics of guanfacine are provided herein. | 03-17-2011 |
20110065797 | DELOXIGLUMIDE AND PROTON PUMP INHIBITORS COMBINATION IN THE TREATMENT OF GASTROINTESTINAL DISORDERS - Cholecystokinin-1 (CCK1) receptor antagonists and the combination of CCK1 receptor antagonists and proton pump inhibitors (PPI) for the treatment of patients suffering from gastrointestinal or related disorders that have failed to completely respond to conventional acid suppression therapy. | 03-17-2011 |
20110082209 | Novel Salts of (4--2-Methylphenyl)Carbonyl]Amino}-3-Methylphenyl)Acetic Acid - A series of novel salt forms of (4-{[(5-{[(3-chlorophenyl)methyl]oxy}-2-methylphenyl)carbonyl]amino}-3-methylphenyl)acetic acid, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine. | 04-07-2011 |
20110112194 | Medicaments Containing Pantothenic Acid - This invention relates to medicaments and their use in the alleviation of inflammation and pain in joints. | 05-12-2011 |
20110118352 | OAT EXTRACTS: REFINING, COMPOSITIONS AND METHODS OF USE - A simple and efficient method for the production of stable, clear, high-potency oat extracts is disclosed. The method employs the use of differential dissociation constants and ultrafiltration to stabilise extracts, prevent hazing, and prevent the loss of functional activity as an anti-irritant and anti-oxidant. Also disclosed are compositions of oat extracts derived from whole oat grains and oatmeal. Further disclosed are compositions of oat extracts for use in cosmetic, nutraceutical, therapeutic medical and veterinary preparations. | 05-19-2011 |
20110144205 | Blood Glutathione as a Biomarker for Screening Asymptomatic Patients at Risk for Heart Failure - The present invention relates to a method for screening an asymptomatic patient at risk for heart failure, said method comprising measuring the concentration of glutathione in a blood sample obtained from said patient. | 06-16-2011 |
20110160307 | Compositions and Methods for Treating Hemorrhagic Conditions - A method of treating a hemorrhagic condition in a subject in need thereof, comprising administering a composition comprising a therapeutically effective amount of Dencichine, a co-solvent, a dispersion supporter, and optionally a cryoprotectant. Compositions and formulations comprising a solid dispersion composition of Dencichine and methods for preparation of same are also described. | 06-30-2011 |
20110172308 | Antagonsim of PGF2a Receptor to Treat Hyertension Characterized by Activation of the Renin-Angiotensin-Aldosterone System - The present invention relates to methods for identifying candidate therapeutics for hypertension. The invention further provides a method for treating hypertension and/or decreasing atherogenesis by administration of an inhibitor of PGF | 07-14-2011 |
20110237673 | Novel NIDDM Regimen - The present invention relates to the use of a short-acting oral hypoglycemic agent and to a novel regimen in the treatment of type 2 diabetes in which the endogenous secretion of insulin is stimulated in connection with meals by administering in connection with the meals a short-acting oral hypoglycaemic agent. Also, the present invention relates to a method of achieving significantly improvement in the glycaemic control by a combined use of repaglinide and metformin in NIDDM patients poorly controlled on metformin alone. | 09-29-2011 |
20110251280 | Stable Aqueous Compositions Comprising Amide-Protected Bioactive Creatine Species and Uses Thereof - The present invention provides amide-protected creatine molecules and compositions, containing one or more bioactive forms of creatine in aqueous compositions, wherein bioactive forms of creatine do not appreciably degrade into creatinine. Also provided are various beneficial effects of administering aqueous compositions having at least one amide-protected creatine molecule. | 10-13-2011 |
20110251281 | Composite Material Comprising High-Molecular-Weight Matrix and Low-Molecular-Weight Organic Compound and Process For Producing Same - Previously reported composite materials comprising a hydrophilic high-molecular-weight matrix and a low-molecular-weight organic compound involve a problem in that: it is difficult to compound a high load of the low-molecular-weight organic compound in the high-molecular-weight matrix; and thus produced composite material yields a high-molecular-weight matrix component that can form a thrombus when contacting with blood. Now, it becomes possible to produce a composite material having an antithrombogenic activity and a high content of a low-molecular-weight organic compound by the present invention comprising the steps of: crosslinking a polymer with an organic acid derivative which is used as a crosslinker in an organic solvent while at the same time embedding the low-molecular-weight organic compound therein; and substituting the organic solvent by water after the production of the high-molecular-weight matrix to effect precipitation and compounding of the low-molecular-weight organic compound in the high-molecular-weight matrix. | 10-13-2011 |
20110275716 | COMPOSITION AND METHOD FOR TREATMENT OF DIABETES - The present invention relates to a method of treating an incretin related disease such as diabetes, obesity and the like by delivery of butyric acid, bile acid, long chain fatty acid, or glutamine to the colon by bypassing the upper digestive tract. | 11-10-2011 |
20110288173 | Use of neboglamine in the treatment of toxicodependency - Use of neboglamine, (S)-4-amino-N(4,4-dimethyl-cyclohexyl)glutamic acid (CR 2249) (CAS Registry Number 163000-63-3), the racemic mixture thereof or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the treatment of toxicodependency induced by drugs such as CNS sedatives such as opiates, barbiturates, benzodiazepines, alcohol, stimulants such as amphetamines and cocaine, and hallucinogens such as LSD, mescalin, cannabis (marijuana) or fencyclidine. | 11-24-2011 |
20110313041 | FOOD SUPPLEMENTS ON THE BASIS OF PANTOTHENIC ACID - The present invention relates to a dietary supplement for the treatment of weakness in metabolic activity containing Pantothenic acid (CoA), its precursors and/or its salts, a process for its production as well as its use. Application areas of the invention are food industry and medicine. | 12-22-2011 |
20120088833 | MODIFIED AMINO ACID FOR THE INHIBITION OF PLATELET AGGREGATION - A method of inhibiting blood platelet aggregation in a mammal is provided. The method comprises the administration of a platelet aggregation inhibiting amount of a modified amino acid or pharmaceutically acceptable salt thereof. | 04-12-2012 |
20120088834 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND - The invention provides crystalline solid forms of (S)-4-((2S,3S)-7-carbamoyl-1,1-diethyl-3-methoxy-1,2,3,4-tetrahydronaphthalen-2-ylamino)-2-cyclohexylmethyl-butyric acid. The invention also provides pharmaceutical compositions comprising such crystalline solid forms, methods of using such crystalline solid forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline solid forms. | 04-12-2012 |
20120101163 | COMPOSITION FOR INHIBITING CANCER METASTASIS - The invention provides a composition for inhibiting cancer metastasis, including: an effective amount of an amino acid hydroxamic acid derivative having a formula as shown as formula (I), formula (II) or formula (III): | 04-26-2012 |
20120115956 | USE OF ISOLEUCINE N-HEXADECANOYL AS A "VOLUMIZING" AND/OR "PLUMPING" AGENT FOR HUMAN SKIN - The invention relates to the cosmetic use of isoleucine N-hexadecanoyl of formula (I): CH | 05-10-2012 |
20120142778 | MICROBIOLOGICAL METHOD FOR SYNTHESIZING CINNAMOYL AMIDE DERIVATIVES OF AMINO ACIDS - Method for the microbiological production of cinnamoyl amide derivatives of amino acids, certain products that result therefrom and uses thereof, especially as antioxidants. | 06-07-2012 |
20120157535 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR DYSMENORRHEA - Disclosed is a prophylactic and/or therapeutic agent for dysmenorrhea and/or associated symptoms thereof. Specifically disclosed is a prophylactic and/or therapeutic agent for dysmenorrhea and/or associated symptoms thereof, which comprises tranilast as an active ingredient thereof. | 06-21-2012 |
20120172448 | Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof - The present application relates to novel substituted 1-benzylcycloalkylcarboxylic acid derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases, and to their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular disorders. | 07-05-2012 |
20120190746 | AFLATOXIN PRODUCTION INHIBITOR AND METHOD FOR CONTROLLING AFLATOXIN CONTAMINATION USING THE SAME - The present invention relates to provide an aflatoxin production inhibitor that inhibits aflatoxin production specifically and efficiently, is highly safe, and is practical, and an efficient production method thereof; and a method for controlling aflatoxin contamination that uses the aflatoxin production inhibitor, specifically relating to an aflatoxin production inhibitor that includes at least one of a dioctatin represented by the following formula (I) and a derivative thereof, as an active ingredient: | 07-26-2012 |
20120190747 | METHOD OF TREATMENT USING FATTY ACID SYNTHESIS INHIBITORS - The present invention relates to natural products that possess fatty acid synthesis inhibitor activity and can be used to treat and prevent diseases such as obesity, cancer, diabetes, fungal infections, | 07-26-2012 |
20120202881 | Novel NIDDM Regimen - The present invention relates to the use of a short-acting oral hypoglycemic agent and to a novel regimen in the treatment of type 2 diabetes in which the endogenous secretion of insulin is stimulated in connection with meals by administering in connection with the meals a short-acting oral hypoglycaemic agent. Also, the present invention relates to a method of achieving significantly improvement in the glycaemic control by a combined use of repaglinide and metformin in NIDDM patients poorly controlled on metformin alone. | 08-09-2012 |
20120238628 | DIHYDRONAPHTHALENE AND NAPHTHALENE DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS - The present invention relates to novel dihydronaphthalene and naphthalene derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor. | 09-20-2012 |
20120264826 | N-Acetyl Beta Alanine Methods of Use - Methods for increasing athletic performance, preventing paresthesia, increasing beta alanine absorption and cell membrane permeability through both passive diffusion and active transport, and increasing the half-life of beta alanine present in a blood stream in a human or animal are disclosed. Each method includes administering to the human or animal a pharmaceutically effective amount of N-Acetyl Beta Alanine or an N-Acetyl Beta Alanine composition. | 10-18-2012 |
20120302641 | BIPHENYL DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS - The present invention is directed to biphenyl derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity. | 11-29-2012 |
20130030053 | NOVEL NIDDM REGIMEN - The present invention relates to the use of a short-acting oral hypoglycemic agent and to a novel regimen in the treatment of type 2 diabetes in which the endogenous secretion of insulin is stimulated in connection with meals by administering in connection with the meals a short-acting oral hypoglycaemic agent. Also, the present invention relates to a method of achieving significantly improvement in the glycaemic control by a combined use of repaglinide and metformin in NIDDM patients poorly controlled on metformin alone. | 01-31-2013 |
20130079412 | Branched 3-phenylpropionic acid derivatives and their use - The present application relates to novel 3-phenylpropionic acid derivatives which carry a branched or cyclic alkyl substituent in the 3-position, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases. | 03-28-2013 |
20130116324 | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES OR IMMUNE DISEASES CONTAINING RAMALIN - The present invention relates to the novel use (anti-inflammatory activity) of Ramalin isolated from the Antarctic lichen | 05-09-2013 |
20130143968 | Methods and compositions for the treatment of diabetes and related symtoms - The present invention is directed to methods and compositions for the treatment of diabetes and related symptoms. It is more specifically directed to compositions including L-glutamine, its salts, or its derivatives, and uses of such compositions in the treatment of diabetes and related symptoms. In a method aspect, the present invention provides a method of treating diabetes. The method involves ingesting 0.05 g/kg body weight to 10.0 g/kg body weight of L-glutamine, an L-glutamine salt or an L-glutamine derivative per day by a person who has diabetes. | 06-06-2013 |
20130150447 | NOVEL OIL-IN-WATER COSMETIC EMULSIONS INCLUDING N-ACYLATED DERIVATIVES HAVING A HIGH MELTING POINT, AND METHODS FOR PREPARING SAME - The oil-in-water cosmetic topical emulsion contains: (1) 95 to 50 wt % of an aqueous phase (P1); and (2) 5 to 50 wt % of a fatty phase (P2), wherein the fatty phase (P2) particularly includes: 0.2 to 60 wt %, specifically 2 to 20 wt %, of at least one N-acylated amino acid derivative of formula (I): R1-C(═O)—NH—CH— (R′ | 06-13-2013 |
20130158122 | EP2 Agonist from Non-Prostanoid Structures Designed as PGE2 Antagonists - A method of treating ocular hypertension, lowering intraocular pressure, pain or inflammation, comprising administering to a mammal a pharmaceutical composition of an EP | 06-20-2013 |
20130178531 | Methods and compositions for the treatment of diverticulosis - The present invention is directed to methods and compositions for the treatment of diverticulosis. It is more specifically directed to compositions including L-glutamine, its salts, or its derivatives, and uses of such compositions in the treatment of diverticulosis. In a method aspect, the present invention provides a method of treating diverticulosis. The method includes ingestion of 0.05 g/kg body weight to 10.0 g/kg body weight of L-glutamine, an L-glutamine salt or an L-glutamine derivative per day by a person who has diverticulosis. | 07-11-2013 |
20130184350 | Novel NIDDM Regimen - The present invention relates to the use of a short-acting oral hypoglycemic agent and to a novel regimen in the treatment of type 2 diabetes in which the endogenous secretion of insulin is stimulated in connection with meals by administering in connection with the meals a short-acting oral hypoglycaemic agent. Also, the present invention relates to a method of achieving significantly improvement in the glycaemic control by a combined use of repaglinide and metformin in NIDDM patients poorly controlled on metformin alone. | 07-18-2013 |
20130225684 | METHODS AND COMPOSITIONS FOR ENHANCEMENT OF VISION PERFORMANCE - A vision performance enhancing composition and method to enhance vision performance using alanylgiutarnine or a salt of alanylglutamine as an active ingredient. | 08-29-2013 |
20130237604 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS - Embodiments of the invention relate to methods and compositions for treating symptoms related to inflammatory conditions and to methods and compositions for treating inflammatory components of common cold, utilizing various method of administration of X-ray contrast media (CM). | 09-12-2013 |
20130253060 | Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences (NIEHS) - Use of sPLA | 09-26-2013 |
20130261185 | Benzamide Derivatives As EP4 Receptor Agonists - A compound of formula (I) or a pharmaceutically acceptable derivative thereof, | 10-03-2013 |
20130289118 | DERIVATIVES OF AMINOALKANOLS, METHOD OF OBTAINING OF AMINOALKANOLS AND THEIR USE - The subject of the invention is a group of new derivatives of aminoalkanols, more specifically [(phenoxy)alkyl]aminoalkanols and [(phenoxy)acyl]aminoalkanols, their method of obtaining and their use for production of a medicine which is used in the prophylaxis, prevention and/or treatment of diseases or symptoms having neurological background and for production a medicine with anticonvulsant activity, which is used in seizures of various origin, also in the limbic system, in myoclonic or sound-induced seizures, in psychomotor epilepsy, as well as relieving neuropathic or inflammatory pain. | 10-31-2013 |
20130345306 | IDENTIFICATION OF C3 COMPLEMENT MOLECULE AT THE SITE OF INJURY TO BLOOD VESSELS IN THE RETINA OF OXYGEN EXPOSED ANIMALS - The invention provides methods to treat oxygen-induced retinopathy using complement factor C3aR antagonists. | 12-26-2013 |
20140018424 | PREVENTIVE EFFECT OF CITRULLINE ON THE SPONTANEOUS DEVELOPMENT OF TUMORS - L-citrulline or a nutraceutically or pharmaceutically acceptable salt thereof for reducing the kinetics of tumour development or reduce the incidence of tumours in aged humans and animals. | 01-16-2014 |
20140066510 | OAT EXTRACTS: REFINING, COMPOSITIONS AND METHODS OF USE - A simple and efficient method for the production of stable, clear, high-potency oat extracts is disclosed. The method employs the use of differential dissociation constants and ultrafiltration to stabilise extracts, prevent hazing, and prevent the loss of functional activity as an anti-irritant and anti-oxidant. Also disclosed are compositions of oat extracts derived from whole oat grains and oatmeal. Further disclosed are compositions of oat extracts for use in cosmetic, nutraceutical, therapeutic medical and veterinary preparations. | 03-06-2014 |
20140128471 | DIHYDRONAPHTHALENE AND NAPHTHALENE DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS - The present invention relates to novel dihydronaphthalene and naphthalene derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor. | 05-08-2014 |
20140194516 | Medicaments Containing Pantothenic Acid - This invention relates to medicaments and their use in the alleviation of inflammation and pain in joints. | 07-10-2014 |
20140194517 | Treatment of Graft-Versus-Host Disease Disorders using RAR Antagonists - The present specification provides RAR antagonist compounds, compositions comprising such RAR antagonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RAR antagonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection. | 07-10-2014 |
20140235718 | PHENOXYETHOXY COMPOUNDS - The present invention provides a compound of the Formula I: | 08-21-2014 |
20140235719 | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES OR IMMUNE DISEASES CONTAINING RAMALIN - The present invention relates to the novel use (anti-inflammatory activity) of Ramalin isolated from the Antarctic lichen | 08-21-2014 |
20140256817 | AMPHIPATHIC AND OTHER DOUBLE-SIDED ALPHA-HELIX MIMETICS BASED ON A 1,2-DIPHENYLACETYLENE SCAFFOLD - Small-molecule scaffolds based on 1,2-diphenylacetylene that accurately replicate the spatial and angular projections of several side chains on both faces of an α-helix, specifically the i and i+7 side chains on one face, and the i and i+2 side chains on the other. The amphipathic α-helix mimetic can be used to disrupt disease-promoting protein-protein interactions that are mediated by α-helices. | 09-11-2014 |
20140309307 | Branched 3-phenylpropionic acid derivatives and their use - The present application relates to novel 3-phenylpropionic acid derivatives which carry a branched or cyclic alkyl substituent in the 3-position, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases. | 10-16-2014 |
20140343150 | NOVEL PHYTOSPHINGOSINE DERIVATIVES, AND COMPOSITION COMPRISING SAME FOR PREVENTING AND TREATING INFLAMMATORY SKIN DISEASES, AUTOIMMUNE DISEASES, AND HYPERKERATOSIS DISEASES - A phytosphingosine derivative of chemical formula IA or IB, and a composition comprising the phytosphingosine derivative for preventing and treating inflammatory skin diseases, autoimmune diseases, and hyperkeratotic diseases. The phytosphingosine derivatives of the present disclosure are involved with transcription factors related to inflammation, autoimmune diseases and hyperkeratotic diseases, the expression and the generation of inflammatory mediators, signal transduction mechanisms, and the expression and the activity of relevant enzymes and the like. | 11-20-2014 |
20140343151 | LEUKOTRIENE B4 ANTAGONIST COMPOUND - The present invention provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof. Also, the present invention provides a pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The present invention further provides methods for treating abdominal aortic aneurysm or atherosclerosis comprising administering a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Formula (I) or pharmaceutically acceptable salt thereof. | 11-20-2014 |
20140350107 | Use of Pan-PPAR Agonists for Prevention and Treatment of Huntington's Disease and Tauopathies - The present invention provides a therapeutic treatment for a neurodegenerative disease with a pan-PPAR agonist, such as bezafibrate. In particular, the present invention provides that pan-PPAR agonists enhance PPAR related responses in both the central nervous system and peripheral tissues in Huntington's Disease (HD) and tauopathy. Therapeutic compositions comprising one or more pan-PPAR agonist(s), and kit thereof, for treating a neurodegenerative disease or disorder are also provided. | 11-27-2014 |
20140350108 | N-Acetyl Beta Alanine Methods of Use - Method for preventing paresthesia in a human is disclosed. The method includes administering to the human an effective amount of N-Acetyl Beta Alanine or an N-Acetyl Beta Alanine composition. | 11-27-2014 |
20140350109 | N-Acetyl Beta Alanine Methods of Use - Method for increasing beta alanine absorption and cell membrane permeability through both passive diffusion and active transport in a human is disclosed. The method includes administering to the human an effective amount of N-Acetyl Beta Alanine or an N-Acetyl Beta Alanine composition. | 11-27-2014 |
20140357720 | NOVEL PHYTOSPHINGOSINE DERIVATIVES, AND A COSMETIC COMPOSITION COMPRISING THE SAME FOR PREVENTING AND AMELIORATING INFLAMMATORY SKIN DISEASES AND HYPERKERATOSIS DISEASES - A phytosphingosine derivatives of chemical formula IA or IB, and a cosmetic composition including the phytosphingosine derivative. The phytosphingosine derivatives are involved with transcription factors related to inflammation and hyperkeratotic diseases, the expression and the generation of inflammatory mediators, signal transduction mechanisms, and the expression and the activity of relevant enzymes and the like. | 12-04-2014 |
20140371316 | DERIVATIVES OF PHENOXYISOBUTYRIC ACID - The present invention provides a process for the synthesis of substituted phenoxymethylpropiomc acid and related compounds. The compounds are useful for inhibiting the formation of AGEs (Advanced Glycation End Products). | 12-18-2014 |
20150031766 | SURFACTANT PEROXYCARBOXYLIC ACID COMPOSITIONS - The present invention relates to compositions including surfactant peroxycarboxylic acid, methods for making these compositions, and methods for reducing the population of a microorganism. | 01-29-2015 |
20150045435 | COMPOUNDS AND METHODS FOR TREATING DIABETES - The invention described herein pertains to compounds, compositions, methods and uses thereof. The compounds described herein are in a class of glucose-lowering drugs useful for treating diabetes. Generally, compounds of the Formula I are described herein. | 02-12-2015 |
20150051285 | Alkylamido Compounds and Uses Thereof - Disclosed herein are compounds that may be specific to PPAR and/or EGF receptors, and methods of making and using same. | 02-19-2015 |
20150080469 | HYDRATED FOOD - Providing a hydrated food which contains theanine and in which theanine content can stably be maintained even when the hydrated food is preserved for a long period of time and the taste threshold of the food can be improved and the peculiar taste can be flavored. The problem can be overcome by a hydrated food containing theanine and pyroglutamic acid. In this case, it is preferable that pH ranges from about 2.8 to about 7.5. Furthermore, it is preferable that a content of pyroglutamic acid ranges from about 1% to about 20% relative to a content of theanine. | 03-19-2015 |
20150133556 | (1S,2S,3S,4R)-3-[(1S)-1-ACETYLAMINO-2-ETHYL-BUTYL]-4-UANIDINO-2-HYDROXYL-C- YCLOPENTYL-1-CARBOXYLIC ACID HYDRATES PHARMACEUTICAL USES THEREOF - The present invention relates to (1S,2S,3S,4R)-3-[(1S)-1-acetylamino-2-ethyl-butyl]-4-guanidino-2-hydroxy-cyclopentyl-1-carboxylic acid hydrates compounds, preparing methods thereof, pharmaceutical compositions containing said compounds and preparing methods thereof, and the clinical uses of said compounds as neuramidinase inhibitors for anti-influenza. | 05-14-2015 |
20150141514 | AGENT FOR PREVENTING DETERIORATION IN VASCULAR ENDOTHELIAL FUNCTION OR IMPROVING VASCULAR ENDOTHELIAL FUNCTION - An agent for enhancing NO production, comprising citrulline or a salt thereof and serine or a salt thereof as an active ingredient. An agent for preventing or ameliorating vascular endothelial malfunction, comprising citrulline or a salt thereof and serine or a salt thereof as an active ingredient. An agent for preventing or ameliorating a symptom caused by vascular endothelial malfunction, comprising citrulline or a salt thereof and serine or a salt thereof as an active ingredient. | 05-21-2015 |
20150148418 | Methods of Treating Hair Related Conditions - Disclosed herein are methods for treating hair related disorders, including compounds that may be specific or modulate PPAR receptors. | 05-28-2015 |
20150148419 | METABOLITES OF (1R-TRANS)-N-[[2-(2,3-DIHYDRO-4-BENZOFURANYL)CYCLOPROPYL]METHYL]PROPANAMI- DE - Isolated metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]-methyl]propanamide, methods for their use, and compositions containing the metabolites. | 05-28-2015 |
20150313860 | METHODS OF REDUCING MILK SOMATIC CELL COUNT - Provided are methods of reducing milk somatic cell count using L-arginine supplementation of lactating ruminant animals during gestation, and/or during the lactation phase post parturition to decrease somatic cell count in milk produced by the animals. | 11-05-2015 |
20150335045 | AVENANTHRAMIDE-ENRICHED OAT PRODUCT - A composition and method for an avenanthramide-enriched, oat-based product having improved health effects. The oat-based product includes an avenanthramide ingredient having avenanthramides 2c:2p:2f in ratios comprising at least one of 1:1:1 or 1:2:2. More particularly, the avenanthramide ingredient may be derived synthetically or recovered from processing raw oats into constituent oat fractions. | 11-26-2015 |
20160010155 | KCNK3 Channel Loss-of-Function Mutants in Familial and Idiopathic Pulmonary Arterial Hypertension | 01-14-2016 |
20160039747 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use - The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-amido-aryl compounds of the following formula (for convenience, collectively referred to herein as “AAA compounds”), which, inter alia, are (selective) retinoic acid receptor α (RARα) agonists. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to (selectively) activate RARα, and in the treatment of diseases and conditions that are mediated by RARα, that are ameliorated by the activation of RARα, etc., including cognitive disorders, memory impairment, memory deficit, senile dementia, Alzheimer's disease, early stage Alzheimer's disease, intermediate stage Alzheimer's disease, late stage Alzheimer's disease, cognitive impairment, and mild cognitive impairment. | 02-11-2016 |
20160060212 | METABOLITES OF (1R-TRANS)-N-[[2-(2,3-DIHYDRO-4-BENZOFURANYL)CYCLOPROPYL]METHYL]PROPANAMI- DE - Isolated metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]-methyl]propanamide, methods for their use, and compositions containing the metabolites. | 03-03-2016 |
20160089351 | USE OF DENCICHINE IN PREPARATION OF DRUG FOR TREATING THROMBOCYTOPENIA - Disclosed are uses of drugs for treating thrombocytopenia, in particular the use of dencichine in preparation of drugs for treating thrombocytopenia. By adding pharmaceutically acceptable conventional adjuvant material, dencichine can be prepared into an oral preparation or an injection. A pharmacodynamic trial shows that the dencichine can effectively inhibit the thrombocytopenia caused by chemotherapy drugs, and treat thrombocytopenic purpura with obvious curative effect and low toxic side effects. | 03-31-2016 |
20160095335 | OAT FRACTIONS WITH ENHANCED AVENANTHRAMIDE CONCENTRATION AND METHODS OF MAKING - Exemplary embodiments provide oat fractions, and methods of producing the oat fractions, of the species | 04-07-2016 |
20160106692 | USE OF X-RAY CONTRAST MEDIA AND RELATED COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF A FILOVIRUS INFECTION - Embodiments disclosed herein relate to certain compositions including X-ray contrast media compounds and/or certain tri-iodinated phenyl compounds and methods of using the same for preventing or treating filovirus infections. | 04-21-2016 |
20160113896 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION - An exemplary embodiment relates to novel protein modulators capable of altering function of the mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction. The invention provides compositions, pharmaceutical preparations and methods of correcting the cellular alteration of a mutant CFTR protein wherein the CFTR mutation is a mutation ΔF508-CFTR, or another mutation of class II. | 04-28-2016 |
20160136118 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF A COMMON COLD AND SYMPTOMS THEREOF - Embodiments of the invention relate to methods and compositions for treating symptoms related to inflammatory conditions and to methods and compositions for treating inflammatory components of a common cold, utilizing various methods of administration od X-ray contrast media (CM). | 05-19-2016 |
20160193168 | Treatment of Pulmonary Arterial Hypertension with Leukotriene Inhibitors | 07-07-2016 |
20160251306 | DIMETHYLBENZOIC ACID COMPOUNDS | 09-01-2016 |